Analyst consensus rating
Novavax Analyst Rating: none
NVAX is rated none by 9 analysts with a $14.00 target. As of 2026-08-27.
Direct answer
Novavax's consensus rating is none.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $14.00.
Forecast evidence checked August 27, 2026.
Get free Novavax email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $9.21
- Average price target
- $14.00
- High price target
- $25.00
- Low price target
- $7.00
- Low target gap
- -24%
- Target upside
- +52%
- High target gap
- +171.4%
- Target range width
- 195.4%
- Consensus rating
- none
- Analysts
- 9
- Evidence date
- August 27, 2026
- Valid through
- September 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Novavax?
Novavax has a verified none consensus. The same dataset has an average price target of $14.00.
How far are Novavax's low and high targets from the recorded price?
The low target implies -24%, while the high target implies +171.4%.
How many analysts are included in Novavax's consensus?
The verified consensus includes 9 analysts.
How is Novavax's target upside or downside calculated?
The average target of $14.00 is divided by the recorded price of $9.21, then one is subtracted to produce +52%. This does not guarantee a future return.
When was Novavax's analyst forecast verified?
The data was verified on 2026-08-27. The dataset is valid through 2026-09-03.